Recent Updates
Recently added Catalysts

Fluconazole

Phase 1

Pharmacology, Clinical | Small molecule | Other |Bayer AG|Last Updated: Apr 29, 2019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment26

FDA Designations

No designations recorded

Clinical trial landscape

Fluconazole · 1 trial · 1 indication

Phase 1 1
NCT03929861Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole FormulationsPharmacology, Clinical
COMPLETED26 Analytics
PHASE1COMPLETED
Bioequivalence Trial to Prove Equal Blood Concentrations of Two Different Fluconazole Formulations
Pharmacology, ClinicalUnlock trial analytics

Study Endpoints

Primary Endpoints

Cmax
Pre-dose and up to 72 hours post-dose

Concentration maximum

AUC0-tlast
Pre-dose and up to 72 hours post-dose

Area under the plasma concentration time curve from time 0 to the last data point above the lower limit of quantification

Secondary Endpoints

Number of participants with Adverse Events as a Measure of safety and tolerability
Up to 7 weeks
tmax
Pre-dose and up to 72 hours post-dose
t½λz
Pre-dose and up to 72 hours post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
Fluconazole, period 1EXPERIMENTALSubjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 1 after an overnight fast of at least 10 hours
Fluconazole, period 2EXPERIMENTALSubjects were randomized to receive a single dose of 150 mg fluconazole on Day 1 of period 2 after an overnight fast of at least 10 hours

Interventions

NameTypeDescription
Fluconazole (BAYT006267) 150 mg capsulesDRUGFluconazole 150 mg
Fluconazole 150 mg capsules (DiflucanTM)DRUGFluconazole 150 mg
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy males in the age between 18 and 50 years * Subjects with a body weight of at least 50 kg and a BMI between 18.5 and 30.0 kg/m2 * Subjects had to be willing to use an acceptable method of contraception (double barrier) during the study and 2 weeks after the end of the s...

Countries:Germany
Unlock Eligibility Criteria